Pneumotox » Drug » Ustekinumab

Ustekinumab

1

Pulmonary involvement has to be evaluated against psoriasis-associated/related ILD (PMID 30560239)

Last update : 22/04/2019

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

1

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

1

I.h Subclinical pulmonary infiltrates/ILD

1

I.m ILD with a granulomatous component

1

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1

X.d Lupus - Lupus syndrome (see also Vd)

1

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XVII.b Opportunistic pulmonary/systemic infections

1

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

1

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

1

XVII.n Legionella pneumophila pneumonia

1

XIX.c BAL: An excess proportion of eosinophils

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist